The White House extended the deadline to impose reciprocal tariffs on most countries until August 1st. What is the impact on manufacturing & supply lines, and what may be next?
With budgetary and staffing cuts at FDA, have approvals of new drugs slowed? DCAT Value Chain Insights looks at the numbers and key trends in new drug approvals thus far in 2025.
Cell and Gene Therapies: How is the Market Faring?
Cell and gene therapies are a niche segment in the global bio/pharmaceutical market. What are leading products, and what are key developments thus far in 2025?
A recent PwC analysis examined the impact of productivity, wages, and overall value in industries with strong and limited exposure to AI. What did it find?
Will New Oral GLP-1 Agonists Be the Next Market Shaker?
The blockbuster success of Novo Nordisk’s Ozempic/Wegovy and Lilly’s Mounjaro/Zepbound, all injectables, have put GLP-1/GIP agonists on the map, but will new oral drugs be a game-changer?
The Push To Onshore US Pharma Manufacturing: What’s on the Table?
Congress is moving forward with proposed legislation to increase both new and reshored pharma manufacturing in the US. What measures are being considered, and where do they stand?
Strong growth is projected for the injectables drugs market, and CDMOs/CMOS are expanding sterile manufacturing & fill–finish capacity. Which companies are expanding, and who is leading the charge?
Pharma Industry-Specific Tariffs: Industry Weighs In
The industry has weighed in on the US government’s potential plan to impose tariffs specific to the pharmaceutical industry. Where does the initiative stand, and what is the industry saying?
Headwinds or Tailwinds: Will the Biotech Sector Rebound in 2025?
Capital flow in the biotech sector has been under pressure with macro factors in the US on tariffs, tax & monetary policy, and drug pricing reforms contributing to uncertainty. But will the tide turn?
New Modalities & More Upsides in the Oncology Drug Market
New modalities, ADCs and bispecific antibodies, accounted for $18 billion in cancer medicine spending in 2024 and are fast-growing on a pipeline basis. What else stands out in the oncology drug market?
